WO2002020568A3 - Mutant peptides derived from bad and their use to identify substances which bind to a member of the bcl-2 family of proteins - Google Patents

Mutant peptides derived from bad and their use to identify substances which bind to a member of the bcl-2 family of proteins Download PDF

Info

Publication number
WO2002020568A3
WO2002020568A3 PCT/US2001/027410 US0127410W WO0220568A3 WO 2002020568 A3 WO2002020568 A3 WO 2002020568A3 US 0127410 W US0127410 W US 0127410W WO 0220568 A3 WO0220568 A3 WO 0220568A3
Authority
WO
WIPO (PCT)
Prior art keywords
bcl
bind
proteins
family
peptides derived
Prior art date
Application number
PCT/US2001/027410
Other languages
French (fr)
Other versions
WO2002020568A2 (en
Inventor
Stephen W Fesik
Robert P Meadows
Mary K Joseph
Edward T Olejniczak
Andrew M Petros
David G Nettesheim
Kerry M Swift
Edmund Matayoshi
Haichao Zhang
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of WO2002020568A2 publication Critical patent/WO2002020568A2/en
Publication of WO2002020568A3 publication Critical patent/WO2002020568A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity

Abstract

The present invention relates to peptides derived from the wild-type human Bad peptide which bind to a member of the Bcl-2 family of proteins. The peptides of the present invention can be used in an assay to identify candidate substances which induce or promote apoptosis in cells.
PCT/US2001/027410 2000-09-06 2001-09-04 Mutant peptides derived from bad and their use to identify substances which bind to a member of the bcl-2 family of proteins WO2002020568A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65639900A 2000-09-06 2000-09-06
US09/656,399 2000-09-06

Publications (2)

Publication Number Publication Date
WO2002020568A2 WO2002020568A2 (en) 2002-03-14
WO2002020568A3 true WO2002020568A3 (en) 2002-09-26

Family

ID=24632879

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/027410 WO2002020568A2 (en) 2000-09-06 2001-09-04 Mutant peptides derived from bad and their use to identify substances which bind to a member of the bcl-2 family of proteins

Country Status (1)

Country Link
WO (1) WO2002020568A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040171809A1 (en) 2002-09-09 2004-09-02 Korsmeyer Stanley J. BH3 peptides and method of use thereof
US20070032417A1 (en) * 2002-12-24 2007-02-08 Walter And Eliza Hall Institute Of Medical Research Peptides and therapeutic uses thereof
WO2005049593A2 (en) * 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
EP2008106A2 (en) 2006-03-31 2008-12-31 Dana-Farber Cancer Institute Methods of determining cellular chemosensitivity
US10393733B2 (en) 2012-09-19 2019-08-27 Dana-Farber Cancer Institute, Inc. Dynamic BH3 profiling
JP6663852B2 (en) 2013-09-19 2020-03-13 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド BH3 profiling method
JP6851978B2 (en) 2015-04-20 2021-03-31 スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド Prediction of alvocidib response by mitochondrial profiling
AU2016253957C1 (en) 2015-04-27 2021-04-01 Dana-Farber Cancer Institute, Inc. High throughput BH3 profiling: a rapid and scalable technology to BH3 profile on low numbers of cells
TR201911032T4 (en) 2015-05-18 2019-08-21 Tolero Pharmaceuticals Inc Alvocidib prodrugs with increased bioavailability.
RU2759963C2 (en) 2015-08-03 2021-11-19 Сумитомо Даиниппон Фарма Онколоджи, Инк. Combination therapies for the treatment of cancer
WO2018094275A1 (en) 2016-11-18 2018-05-24 Tolero Pharmaceuticals, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
EP3362471B1 (en) 2016-12-19 2021-11-17 Sumitomo Dainippon Pharma Oncology, Inc. Profiling peptides and methods for sensitivity profiling
US11497756B2 (en) 2017-09-12 2022-11-15 Sumitomo Pharma Oncology, Inc. Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1 inhibitor alvocidib
US11034710B2 (en) 2018-12-04 2021-06-15 Sumitomo Dainippon Pharma Oncology, Inc. CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
US11793802B2 (en) 2019-03-20 2023-10-24 Sumitomo Pharma Oncology, Inc. Treatment of acute myeloid leukemia (AML) with venetoclax failure

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998012328A2 (en) * 1996-09-20 1998-03-26 Idun Pharmaceuticals, Incorporated Human bad polypeptides, encoding nucleic acids and methods of use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998012328A2 (en) * 1996-09-20 1998-03-26 Idun Pharmaceuticals, Incorporated Human bad polypeptides, encoding nucleic acids and methods of use

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATTA SR ET AL.: "14-3-3 proteins and survival kinases cooperate to inactivate BAD by BH3 domain phosphorylation", MOLECULAR CELL BIOLOGY, vol. 6, July 2000 (2000-07-01), XX, XX, pages 41 - 51, XP002198262 *
KELEKAR A ET AL.: "Bad is a BH3 domain-containing protein that forms an inactivating dimer with Bcl-xL", MOLECULAR AND CELLULAR BIOLOGY, vol. 17, no. 12, December 1997 (1997-12-01), WASHINGTON, DC, US, pages 7040 - 7046, XP002198264, ISSN: 0270-7306 *
OTTILIE ET AL.: "Dimerization properties of human BAD", JOURNAL OF BIOLOGICAL CHEMISTRY., vol. 272, no. 49, 5 December 1997 (1997-12-05), AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD., US, pages 30866 - 30872, XP002198263, ISSN: 0021-9258 *
PETROS AM ET AL.: "Rationale for Bcl-xL/Bad peptide complex formation from structure, mutagenesis, and biophysical studies", PROTEIN SCIENCE., vol. 9, December 2000 (2000-12-01), CAMBRIDGE UNIVERSITY PRESS, CAMBRIDGE., GB, pages 2528 - 2534, XP001073551, ISSN: 0961-8368 *

Also Published As

Publication number Publication date
WO2002020568A2 (en) 2002-03-14

Similar Documents

Publication Publication Date Title
WO2002030959A3 (en) Peptides derived from smac (diablo) and methods of use therefor
WO2002020568A3 (en) Mutant peptides derived from bad and their use to identify substances which bind to a member of the bcl-2 family of proteins
NZ504114A (en) Vitamin k-dependent polypeptides such as protein C where substitution at amino acid sites 11, 12, 29, 33 or 34 affects membrane binding affinity of the protein and ultimately blood clotting ability
BR0009206A (en) Protein isolation and analysis
AU2001286730A1 (en) An iap binding peptide or polypeptide and methods of using the same
IL200608A0 (en) Methods for the detection of 193p1e1b protein and use of compositions containing a 193p1e1b protein or an antibody binding thereto
AU2002219960A1 (en) Molecules of the card-related protein family and uses thereof
WO2001057198A3 (en) Methods of generating protein expression arrays and the use thereof in rapid screening
DE60129239D1 (en) KIT AND PROCESS FOR DETERMINING PROTEIN ESM-1
EP1136547A3 (en) Adamts polypeptides, nucleic acids encoding them, and uses thereof
AU2002233424A1 (en) Peptides having affinity for the GP120 viral protein and use thereof
AU2002214542A1 (en) Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof
AU8542701A (en) Stress proteins and peptides and methods of use thereof
AU2001250999A1 (en) Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof
AU2002304163A1 (en) Polypeptide unstabilizing protein in cells under aerobic conditions and DNA encoding the same
AU2002340881A1 (en) Concentration of protein and/or peptides samples
AU2002239256A1 (en) Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof
WO2002010417A3 (en) Methods and compositions for the construction and use of viral envelops as display particles
WO2002040530A3 (en) Mutant bcl-2 proteins and uses thereof
EP1134286A3 (en) Adamts polypeptides, nucleic acids encoding them, and uses thereof
AU2001288363A1 (en) Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof
WO2003100075A3 (en) Bsnd nucleic acids and proteins
AU2001229697A1 (en) Novel molecules of the card-related protein family and uses thereof
AU2002338856A1 (en) Peptides derived from the superantigen (sag) env protein of herv-k18 and their use in obtaining sag-inhibitory antibodies and in vaccination against sag
WO2004035733A3 (en) Isolated human hepsin/46 proteins, nucleic acid molecules encoding human hepsin/46 proteins, and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP MX

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): CA JP MX

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP